Professor Ian Davis

Honorary Associate
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone +61 3 9094 9546
Fax +61 3 9899 9137

Map

Selected grants

2014

  • Pain free TRUS B trial; Davis I; DVC Research/Bridging Support Grant.

2013

  • ANZUP - Support for Cancer Clinical Trials; Davis I; Cancer Australia/Support for Cancer Clinical Trials Program - National Cancer Cooperative Trials Groups.

2011

  • START Trial: Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer; Millar J, Bolton D, Frydenberg M, Patel M, Williams S, Davis I, Stockler M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2010

  • Australian and new Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Davis I; Cancer Australia/Support for Cancer Clinical Trials - Existing National Cooperative Oncology groups.

2009

  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Davis I; Cancer Australia/Support for Cancer Clinical Trials - Existing National Cooperative Oncology groups.
  • SORCE Trial: A Phase III Randomised Double-blind study comparing Sorafenib with placebo inpatients with resected primary renal cell carcinoma at high or intermediate risk of relapse; Davis I; Medical Research Council (UK)/Research Support.

2008

  • For merger between the ANZGCTG and the Australian Prostate and Urogenital Cancar Group (APUG); Toner G, Davis I; Cancer Australia/Support for Cancer Clinical Trials.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Grimison, P., Houghton, B., Chatfield, M., Toner, G., Davis, I., Martin, J., Hovey, E., Stockler, M. (2013). Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International, 112(2), E35-E43. [More Information]
  • Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]
  • Svobodova, S., Browning, J., MacGregor, D., Pollara, G., Scolyer, R., Murali, R., Thompson, J., Deb, S., Azad, A., Davis, I., et al (2011). Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 47(3), 460-469. [More Information]
  • Lawrentschuk, N., Lee, F., Jones, G., Rigopoulos, A., Mountain, A., O'Keefe, G., Papenfuss, A., Bolton, D., Davis, I., Scott, A. (2010). Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT. Urologic Oncology: seminars and original investigations, 29(4), 411-420. [More Information]
  • Ebert, L., Liu, Y., Clements, C., Robson, N., Jackson, H., Markby, J., Dimopoulos, N., Tan, B., Luescher, I., Davis, I., et al (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Research, 69(3), 1046-1054. [More Information]
  • Gedye, C., Quirk, J., Browning, J., Svobodová, S., John, T., Sluka, P., Dunbar, P., Corbeil, D., Cebon, J., Davis, I. (2009). Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunology, Immunotherapy: other biological response modifications, 58(10), 1635-1646. [More Information]
  • Klein, O., Ebert, L., Nicholaou, T., Browning, J., Russell, S., Zuber, M., Jackson, H., Dimopoulos, N., Tan, B., Hoos, A., Davis, I., et al (2009). Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clinical Cancer Research, 15(7), 2507-2513. [More Information]
  • Nicholaou, T., Ebert, L., Davis, I., McArthur, G., Jackson, H., Dimopoulos, N., Tan, B., Maraskovsky, E., Miloradovic, L., Hopkins, W., et al (2009). Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research. [More Information]
  • Kelly, M., Lee, S., Lee, F., Smyth, F., Davis, I., Brechbiel, M., Scott, A. (2009). Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. The Prostate, 69(1), 92-104. [More Information]
  • Davis, I. (2008). Advances in the treatment of castrate-resistant prostate cancer. Asia Pacific Journal of Oncology and Hematology, 1, 52-55.
  • Davis, I., Desai, J. (2008). Clinical use of therapies targeting tumor vasculature and stroma. Current Cancer Drug Targets, 8(6), 498-508. [More Information]
  • John, T., Caballero, O., Svobodová, S., Kong, A., Chua, R., Browning, J., Fortunato, S., Deb, S., Hsu, M., Hsu, M., Davis, I., et al (2008). ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. Clinical Cancer Research, 14(11), 3291-3298. [More Information]
  • Frederiksen, K., Lundsgaard, D., Freeman, J., Hughes, S., Holm, T., Skrumsager, B., Petri, A., Hansen, L., McArthur, G., Davis, I., et al (2008). IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunology, Immunotherapy: other biological response modifications, 57(10), 1439-1449. [More Information]
  • Lawrentschuk, N., Appu, S., Chao, I., Chan, Y., Rogerson, J., Davis, I. (2008). Peripheral primitive neuroectodermal tumor arising from the seminal vesicle. Urologia Internationalis, 80(2), 212-215. [More Information]
  • John, T., Black, M., Toro, T., Leader, D., Gedye, C., Davis, I., Guilford, P., Cebon, J. (2008). Predicting clinical outcome through molecular profiling in stage III melanoma. Clinical Cancer Research, 14(16), 5173-5180. [More Information]
  • Pook, D., Davis, I. (2008). Targeted therapies in renal cell carcinoma. Cancer Forum, 32, 155-158.
  • Pezaro, C., Davis, I. (2008). Targeted therapies in the treatment of renal cell carcinoma. Current Medicinal Chemistry, 15(12), 1166-1174. [More Information]
  • Ebert, L., Bee, S., Browning, J., Svobodova, S., Russell, S., Kirkpatrick, N., Gedye, C., Moss, D., Ng, S., MacGregor, D., Davis, I., et al (2008). The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. Cancer Research, 68(8), 3001-2009. [More Information]
  • Grossmann, M., Premaratne, E., Desai, J., Davis, I. (2008). Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clinical Endocrinology, 69(4), 669-672. [More Information]
  • Scott, A., Tebbutt, N., Lee, F., Cavicchiolo, T., Liu, Z., Gill, S., Poon, A., Hopkins, W., Smyth, F., Davis, I., et al (2007). A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clinical Cancer Research, 13(11), 3286-3292. [More Information]
  • Davis, I., Wiseman, G., Lee, F., Gansen, D., Hopkins, W., Papenfuss, A., Liu, Z., Moynihan, T., Croghan, G., Adjei, A., et al (2007). A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immunity, 7, 13- 1-13 - 8. [More Information]
  • Davis, I., Liu, Z., Saunders, W., Lee, F., Spirkoska, V., Hopkins, W., Smyth, F., Chong, G., Papenfuss, A., Chappell, B., et al (2007). A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immunity, 7(August), 14-1-14-9. [More Information]
  • Davis, I., Skrumsager, B., Cebon, J., Nicholaou, T., Barlow, J., Moller, N., Skak, K., Lundsgaard, D., Frederiksen, K., Thygesen, P., et al (2007). An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clinical Cancer Research, 13(12), 3630-3636. [More Information]
  • Lawrentschuk, N., Davis, I., Bolton, D., Scott, A. (2007). Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. International Journal of Urology, 14(2), 89-95. [More Information]
  • Chew, S., Wood, B., Canaan, C., Browning, J., MacGregor, D., Davis, I., Cebon, J., Tait, B., McNaughton, D. (2007). Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody. Tissue Antigens: immune response genetics, 69(Supplement 1), 252-258. [More Information]
  • Cebon, J., Gedye, C., John, T., Davis, I. (2007). Immunotherapy of advanced or metastatic melanoma. Clinical advances in hematology & oncology, 5(12), 994-1006. [More Information]
  • Davis, I., Skak, K., Smyth, M., Kristjansen, P., Miller, D., Sivakumar, P. (2007). Interleukin-21 signaling: functions in cancer and autoimmunity. Clinical Cancer Research, 13(23), 6926-6932. [More Information]
  • Davis, I., Toner, G., Broad, A., Campano, L., Rosenthal, M. (2007). Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer. Asia-Pacific Journal of Clinical Oncology, 3(3), 148-155.
  • Lawrentschuk, N., Bolton, D., Davis, I., Scott, A. (2007). Renal cell cancer and positron emission tomography - an evolving diagnostic and therapeutic relationship. Current Medical Imaging Reviews, 3, 17-26.
  • Desai, J., Gurney, H., Pavlakis, N., McArthur, G., Davis, I. (2007). Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology, 3(4), 167-176. [More Information]
  • Nicholaou, T., Wong, R., Davis, I. (2007). Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. The Lancet, 369(9577), 1923-1924. [More Information]
  • Gan, H., Mitchell, P., Galettis, P., Davis, I., Cebon, J., De Souza, P., Links, M. (2006). A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 58(2), 157-164. [More Information]
  • Davis, I., Chen, Q., Morris, L., Quirk, J., Stanley, M., Tavarnesi, M., Parente, P., Cavicchiolo, T., Hopkins, W., Jackson, H., et al (2006). Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. Journal of Immunotherapy, 29(5), 499-511. [More Information]
  • Lim, E., Browning, J., MacGregor, D., Davis, I., Cebon, J. (2006). Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. Melanoma Research: a journal for basic, translational and clinical research in melanoma, 16(4), 347-355. [More Information]
  • Nicholaou, T., Ebert, L., Davis, I., Robson, N., Klein, O., Maraskovsky, E., Chen, W., Cebon, J. (2006). Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunology and Cell Biology, 84(3), 303-317. [More Information]
  • Goldstein, D., Ackland, S., Bell, D., Olver, I., Davis, I., Rosenthal, M., Toner, G., Pinel, M., Byrne, M. (2006). Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Investigational New Drugs, 24(5), 429-434. [More Information]
  • Lawrentschuk, N., Davis, I., Bolton, D., Scott, A. (2006). Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU International, 97(5), 916-922. [More Information]
  • Lawrentschuk, N., Davis, I., Bolton, D., Scott, A. (2006). Positron emission tomography and molecular imaging of the prostate: an update. BJU International, 97(5), 923-931. [More Information]
  • Jackson, H., Dimopoulos, N., Mifsud, N., Tai, T., Chen, Q., Svobodova, S., Browning, J., Luescher, I., Stockert, E., Old, L., Davis, I., et al (2006). Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. Journal of Immunology, 176(10), 5908-5917. [More Information]
  • Barrow, C., Browning, J., MacGregor, D., Davis, I., Sturrock, S., Jungbluth, A., Cebon, J. (2006). Tumor antigen expression in melanoma varies according to antigen and stage. Clinical Cancer Research, 12(3), 764-771. [More Information]
  • Lawrentschuk, N., Rigopoulos, A., Lee, F., Davis, I., Scott, A., Bolton, D. (2006). Xenografting tumour beneath the renal capsule using modern surgical equipment. European Surgical Research, 38(3), 340-346. [More Information]
  • Davis, I., Kiers, L., MacGregor, L., Quinn, M., Arezzo, J., Green, M., Rosenthal, M., Chia, M., Michael, M., Bartley, P., et al (2005). A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clinical Cancer Research, 11(5), 1890-1898. [More Information]
  • Lawewntschuk, N., Poon, A., Foo, S., Putra, L., Murone, C., Davis, I., Bolton, D., Scott, A. (2005). Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU International, 96(4), 540-546. [More Information]
  • John, T., Cebon, J., Davis, I. (2005). Biochemotherapy for the treatment of metastatic melanoma at the Austin Hospital. Asia-Pacific Journal of Clinical Oncology, 1, 81-87.
  • Davis, I., Zeier, M. (2005). Can't cope with 'acopia'. Internal Medicine Journal, 35(9), 574; author reply 574-5. [More Information]
  • Chen, Q., Jackson, H., Shackleton, M., Parente, P., Hopkins, W., Sturrock, S., MacGregor, D., Maraskovsky, E., Tai, T., Dimopoulos, N., Davis, I., et al (2005). Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immunity, 5, 5-1-5-7. [More Information]
  • Scott, A., Liu, Z., Murone, C., Johns, T., MacGregor, D., Smyth, F., Lee, F., Cebon, J., Davis, I., Hopkins, W., et al (2005). Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immunity, 5, 3-1-3-12. [More Information]
  • Harris, M., Berlangieri, S., Cebon, J., Davis, I., Scott, A. (2005). Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma. Molecular Imaging and Biology, 7(4), 304-308. [More Information]
  • Chong, G., Lee, F., Hopkins, W., Tebbutt, N., Cebon, J., Mountain, A., Chappell, B., Papenfuss, A., Schleyer, P., Davis, I., et al (2005). Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clinical Cancer Research, 11(13), 4818-4826. [More Information]
  • Murphy, R., Green, S., Ritter, G., Cohen, L., Ryan, D., Woods, W., Rubira, M., Cebon, J., Davis, I., Sjolander, A., et al (2005). Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Preparative Biochemistry and Biotechnology, 35(2), 119-134. [More Information]
  • Schnurr, M., Chen, Q., Shin, A., Chen, W., Toy, T., Jenderek, C., Green, S., Miloradovic, L., Drane, D., Davis, I., et al (2005). Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood, 105(6), 2465-2472. [More Information]
  • John, T., Davis, I. (2005). Ventricular metastasis resulting in disseminated intravascular coagulation. World Journal of Surgical Oncology, 3(1), 29. [More Information]
  • Putra, L., Lawrentschuk, N., Ballok, Z., Hannah, A., Poon, A., Tauro, A., Davis, I., Hicks, R., Bolton, D., Scott, A. (2004). 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. International Journal of Urology, 64(6), 1202-1207. [More Information]
  • Mitchell, P., Basser, R., Chipman, M., Grigg, A., Mansfield, R., Cebon, J., Davis, I., Appia, F., Green, M. (2004). A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Annals of Oncology, 15(4), 585-589. [More Information]
  • Jackson, H., Dimopoulos, N., Chen, Q., Luke, T., Tai, T., Maraskovsky, E., Old, L., Davis, I., Cebon, J., Chen, W. (2004). A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. Journal of Immunological Methods, 291(1-2). [More Information]
  • Chen, Q., Jackson, H., Parente, P., Luke, T., Rizkalla, M., Tai, T., Zhu, H., Mifsud, N., Dimopoulos, N., Masterman, K., Davis, I., et al (2004). Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 101(25), 9363-9368. [More Information]
  • Vaughan, H., Svobodova, S., MacGregor, D., Sturrock, S., Jungbluth, A., Browning, J., Davis, I., Parente, P., Chen, Y., Stockert, E., et al (2004). Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clinical Cancer Research, 10(24), 8396-8404. [More Information]
  • Davis, I., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., et al (2004). Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 101(29), 10697-10702. [More Information]
  • Schnurr, M., Toy, T., Shin, A., Hartmann, G., Rothenfusser, S., Soellner, J., Davis, I., Cebon, J., Maraskovsky, E. (2004). Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood, 103(4), 1391-1397. [More Information]
  • Shackleton, M., Davis, I., Hopkins, W., Jackson, H., Dimopoulos, N., Tai, T., Chen, Q., Parente, P., Jefford, M., Masterman, K., et al (2004). The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immunity, 4, 9-1-9 - 11. [More Information]
  • Mitchell, P., Basser, R., Chipman, M., Grigg, A., Cebon, J., Davis, I., Zalcberg, J., Ng, S., Appia, F., Green, M. (2003). A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours. Annals of Oncology, 14(5), 788-794. [More Information]
  • Gunawardana, D., Basser, R., Davis, I., Cebon, J., Mitchell, P., Underhill, C., Kilpatrick, T., Reardon, K., Green, M., Bardy, P., et al (2003). A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clinical Cancer Research, 9(6), 2056-2065. [More Information]
  • Jefford, M., Schnurr, M., Toy, T., Masterman, K., Shin, A., Beecroft, T., Tai, T., Shortman, K., Shackleton, M., Davis, I., et al (2003). Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood, 102(5), 1753-1763. [More Information]
  • Cebon, J., Jäger, E., Shackleton, M., Gibbs, P., Davis, I., Hopkins, W., Gibbs, S., Chen, Q., Karbach, J., Jackson, H., et al (2003). Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immunity, 3, 1-18. [More Information]

2013

  • Grimison, P., Houghton, B., Chatfield, M., Toner, G., Davis, I., Martin, J., Hovey, E., Stockler, M. (2013). Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International, 112(2), E35-E43. [More Information]
  • Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., Harrup, R., Underhill, C., Kichenadasse, G., Singhal, N., Boland, A., McDonald, A., et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6), 1561-1568. [More Information]

2011

  • Svobodova, S., Browning, J., MacGregor, D., Pollara, G., Scolyer, R., Murali, R., Thompson, J., Deb, S., Azad, A., Davis, I., et al (2011). Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 47(3), 460-469. [More Information]

2010

  • Lawrentschuk, N., Lee, F., Jones, G., Rigopoulos, A., Mountain, A., O'Keefe, G., Papenfuss, A., Bolton, D., Davis, I., Scott, A. (2010). Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT. Urologic Oncology: seminars and original investigations, 29(4), 411-420. [More Information]

2009

  • Ebert, L., Liu, Y., Clements, C., Robson, N., Jackson, H., Markby, J., Dimopoulos, N., Tan, B., Luescher, I., Davis, I., et al (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Research, 69(3), 1046-1054. [More Information]
  • Gedye, C., Quirk, J., Browning, J., Svobodová, S., John, T., Sluka, P., Dunbar, P., Corbeil, D., Cebon, J., Davis, I. (2009). Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunology, Immunotherapy: other biological response modifications, 58(10), 1635-1646. [More Information]
  • Klein, O., Ebert, L., Nicholaou, T., Browning, J., Russell, S., Zuber, M., Jackson, H., Dimopoulos, N., Tan, B., Hoos, A., Davis, I., et al (2009). Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clinical Cancer Research, 15(7), 2507-2513. [More Information]
  • Nicholaou, T., Ebert, L., Davis, I., McArthur, G., Jackson, H., Dimopoulos, N., Tan, B., Maraskovsky, E., Miloradovic, L., Hopkins, W., et al (2009). Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research. [More Information]
  • Kelly, M., Lee, S., Lee, F., Smyth, F., Davis, I., Brechbiel, M., Scott, A. (2009). Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. The Prostate, 69(1), 92-104. [More Information]

2008

  • Davis, I. (2008). Advances in the treatment of castrate-resistant prostate cancer. Asia Pacific Journal of Oncology and Hematology, 1, 52-55.
  • Davis, I., Desai, J. (2008). Clinical use of therapies targeting tumor vasculature and stroma. Current Cancer Drug Targets, 8(6), 498-508. [More Information]
  • John, T., Caballero, O., Svobodová, S., Kong, A., Chua, R., Browning, J., Fortunato, S., Deb, S., Hsu, M., Hsu, M., Davis, I., et al (2008). ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. Clinical Cancer Research, 14(11), 3291-3298. [More Information]
  • Frederiksen, K., Lundsgaard, D., Freeman, J., Hughes, S., Holm, T., Skrumsager, B., Petri, A., Hansen, L., McArthur, G., Davis, I., et al (2008). IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunology, Immunotherapy: other biological response modifications, 57(10), 1439-1449. [More Information]
  • Lawrentschuk, N., Appu, S., Chao, I., Chan, Y., Rogerson, J., Davis, I. (2008). Peripheral primitive neuroectodermal tumor arising from the seminal vesicle. Urologia Internationalis, 80(2), 212-215. [More Information]
  • John, T., Black, M., Toro, T., Leader, D., Gedye, C., Davis, I., Guilford, P., Cebon, J. (2008). Predicting clinical outcome through molecular profiling in stage III melanoma. Clinical Cancer Research, 14(16), 5173-5180. [More Information]
  • Pook, D., Davis, I. (2008). Targeted therapies in renal cell carcinoma. Cancer Forum, 32, 155-158.
  • Pezaro, C., Davis, I. (2008). Targeted therapies in the treatment of renal cell carcinoma. Current Medicinal Chemistry, 15(12), 1166-1174. [More Information]
  • Ebert, L., Bee, S., Browning, J., Svobodova, S., Russell, S., Kirkpatrick, N., Gedye, C., Moss, D., Ng, S., MacGregor, D., Davis, I., et al (2008). The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. Cancer Research, 68(8), 3001-2009. [More Information]
  • Grossmann, M., Premaratne, E., Desai, J., Davis, I. (2008). Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clinical Endocrinology, 69(4), 669-672. [More Information]

2007

  • Scott, A., Tebbutt, N., Lee, F., Cavicchiolo, T., Liu, Z., Gill, S., Poon, A., Hopkins, W., Smyth, F., Davis, I., et al (2007). A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clinical Cancer Research, 13(11), 3286-3292. [More Information]
  • Davis, I., Wiseman, G., Lee, F., Gansen, D., Hopkins, W., Papenfuss, A., Liu, Z., Moynihan, T., Croghan, G., Adjei, A., et al (2007). A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immunity, 7, 13- 1-13 - 8. [More Information]
  • Davis, I., Liu, Z., Saunders, W., Lee, F., Spirkoska, V., Hopkins, W., Smyth, F., Chong, G., Papenfuss, A., Chappell, B., et al (2007). A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immunity, 7(August), 14-1-14-9. [More Information]
  • Davis, I., Skrumsager, B., Cebon, J., Nicholaou, T., Barlow, J., Moller, N., Skak, K., Lundsgaard, D., Frederiksen, K., Thygesen, P., et al (2007). An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clinical Cancer Research, 13(12), 3630-3636. [More Information]
  • Lawrentschuk, N., Davis, I., Bolton, D., Scott, A. (2007). Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. International Journal of Urology, 14(2), 89-95. [More Information]
  • Chew, S., Wood, B., Canaan, C., Browning, J., MacGregor, D., Davis, I., Cebon, J., Tait, B., McNaughton, D. (2007). Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody. Tissue Antigens: immune response genetics, 69(Supplement 1), 252-258. [More Information]
  • Cebon, J., Gedye, C., John, T., Davis, I. (2007). Immunotherapy of advanced or metastatic melanoma. Clinical advances in hematology & oncology, 5(12), 994-1006. [More Information]
  • Davis, I., Skak, K., Smyth, M., Kristjansen, P., Miller, D., Sivakumar, P. (2007). Interleukin-21 signaling: functions in cancer and autoimmunity. Clinical Cancer Research, 13(23), 6926-6932. [More Information]
  • Davis, I., Toner, G., Broad, A., Campano, L., Rosenthal, M. (2007). Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer. Asia-Pacific Journal of Clinical Oncology, 3(3), 148-155.
  • Lawrentschuk, N., Bolton, D., Davis, I., Scott, A. (2007). Renal cell cancer and positron emission tomography - an evolving diagnostic and therapeutic relationship. Current Medical Imaging Reviews, 3, 17-26.
  • Desai, J., Gurney, H., Pavlakis, N., McArthur, G., Davis, I. (2007). Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology, 3(4), 167-176. [More Information]
  • Nicholaou, T., Wong, R., Davis, I. (2007). Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. The Lancet, 369(9577), 1923-1924. [More Information]

2006

  • Gan, H., Mitchell, P., Galettis, P., Davis, I., Cebon, J., De Souza, P., Links, M. (2006). A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 58(2), 157-164. [More Information]
  • Davis, I., Chen, Q., Morris, L., Quirk, J., Stanley, M., Tavarnesi, M., Parente, P., Cavicchiolo, T., Hopkins, W., Jackson, H., et al (2006). Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. Journal of Immunotherapy, 29(5), 499-511. [More Information]
  • Lim, E., Browning, J., MacGregor, D., Davis, I., Cebon, J. (2006). Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. Melanoma Research: a journal for basic, translational and clinical research in melanoma, 16(4), 347-355. [More Information]
  • Nicholaou, T., Ebert, L., Davis, I., Robson, N., Klein, O., Maraskovsky, E., Chen, W., Cebon, J. (2006). Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunology and Cell Biology, 84(3), 303-317. [More Information]
  • Goldstein, D., Ackland, S., Bell, D., Olver, I., Davis, I., Rosenthal, M., Toner, G., Pinel, M., Byrne, M. (2006). Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Investigational New Drugs, 24(5), 429-434. [More Information]
  • Lawrentschuk, N., Davis, I., Bolton, D., Scott, A. (2006). Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU International, 97(5), 916-922. [More Information]
  • Lawrentschuk, N., Davis, I., Bolton, D., Scott, A. (2006). Positron emission tomography and molecular imaging of the prostate: an update. BJU International, 97(5), 923-931. [More Information]
  • Jackson, H., Dimopoulos, N., Mifsud, N., Tai, T., Chen, Q., Svobodova, S., Browning, J., Luescher, I., Stockert, E., Old, L., Davis, I., et al (2006). Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. Journal of Immunology, 176(10), 5908-5917. [More Information]
  • Barrow, C., Browning, J., MacGregor, D., Davis, I., Sturrock, S., Jungbluth, A., Cebon, J. (2006). Tumor antigen expression in melanoma varies according to antigen and stage. Clinical Cancer Research, 12(3), 764-771. [More Information]
  • Lawrentschuk, N., Rigopoulos, A., Lee, F., Davis, I., Scott, A., Bolton, D. (2006). Xenografting tumour beneath the renal capsule using modern surgical equipment. European Surgical Research, 38(3), 340-346. [More Information]

2005

  • Davis, I., Kiers, L., MacGregor, L., Quinn, M., Arezzo, J., Green, M., Rosenthal, M., Chia, M., Michael, M., Bartley, P., et al (2005). A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clinical Cancer Research, 11(5), 1890-1898. [More Information]
  • Lawewntschuk, N., Poon, A., Foo, S., Putra, L., Murone, C., Davis, I., Bolton, D., Scott, A. (2005). Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU International, 96(4), 540-546. [More Information]
  • John, T., Cebon, J., Davis, I. (2005). Biochemotherapy for the treatment of metastatic melanoma at the Austin Hospital. Asia-Pacific Journal of Clinical Oncology, 1, 81-87.
  • Davis, I., Zeier, M. (2005). Can't cope with 'acopia'. Internal Medicine Journal, 35(9), 574; author reply 574-5. [More Information]
  • Chen, Q., Jackson, H., Shackleton, M., Parente, P., Hopkins, W., Sturrock, S., MacGregor, D., Maraskovsky, E., Tai, T., Dimopoulos, N., Davis, I., et al (2005). Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immunity, 5, 5-1-5-7. [More Information]
  • Scott, A., Liu, Z., Murone, C., Johns, T., MacGregor, D., Smyth, F., Lee, F., Cebon, J., Davis, I., Hopkins, W., et al (2005). Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immunity, 5, 3-1-3-12. [More Information]
  • Harris, M., Berlangieri, S., Cebon, J., Davis, I., Scott, A. (2005). Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma. Molecular Imaging and Biology, 7(4), 304-308. [More Information]
  • Chong, G., Lee, F., Hopkins, W., Tebbutt, N., Cebon, J., Mountain, A., Chappell, B., Papenfuss, A., Schleyer, P., Davis, I., et al (2005). Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clinical Cancer Research, 11(13), 4818-4826. [More Information]
  • Murphy, R., Green, S., Ritter, G., Cohen, L., Ryan, D., Woods, W., Rubira, M., Cebon, J., Davis, I., Sjolander, A., et al (2005). Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Preparative Biochemistry and Biotechnology, 35(2), 119-134. [More Information]
  • Schnurr, M., Chen, Q., Shin, A., Chen, W., Toy, T., Jenderek, C., Green, S., Miloradovic, L., Drane, D., Davis, I., et al (2005). Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood, 105(6), 2465-2472. [More Information]
  • John, T., Davis, I. (2005). Ventricular metastasis resulting in disseminated intravascular coagulation. World Journal of Surgical Oncology, 3(1), 29. [More Information]

2004

  • Putra, L., Lawrentschuk, N., Ballok, Z., Hannah, A., Poon, A., Tauro, A., Davis, I., Hicks, R., Bolton, D., Scott, A. (2004). 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. International Journal of Urology, 64(6), 1202-1207. [More Information]
  • Mitchell, P., Basser, R., Chipman, M., Grigg, A., Mansfield, R., Cebon, J., Davis, I., Appia, F., Green, M. (2004). A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Annals of Oncology, 15(4), 585-589. [More Information]
  • Jackson, H., Dimopoulos, N., Chen, Q., Luke, T., Tai, T., Maraskovsky, E., Old, L., Davis, I., Cebon, J., Chen, W. (2004). A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. Journal of Immunological Methods, 291(1-2). [More Information]
  • Chen, Q., Jackson, H., Parente, P., Luke, T., Rizkalla, M., Tai, T., Zhu, H., Mifsud, N., Dimopoulos, N., Masterman, K., Davis, I., et al (2004). Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 101(25), 9363-9368. [More Information]
  • Vaughan, H., Svobodova, S., MacGregor, D., Sturrock, S., Jungbluth, A., Browning, J., Davis, I., Parente, P., Chen, Y., Stockert, E., et al (2004). Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clinical Cancer Research, 10(24), 8396-8404. [More Information]
  • Davis, I., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., et al (2004). Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 101(29), 10697-10702. [More Information]
  • Schnurr, M., Toy, T., Shin, A., Hartmann, G., Rothenfusser, S., Soellner, J., Davis, I., Cebon, J., Maraskovsky, E. (2004). Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood, 103(4), 1391-1397. [More Information]
  • Shackleton, M., Davis, I., Hopkins, W., Jackson, H., Dimopoulos, N., Tai, T., Chen, Q., Parente, P., Jefford, M., Masterman, K., et al (2004). The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immunity, 4, 9-1-9 - 11. [More Information]

2003

  • Mitchell, P., Basser, R., Chipman, M., Grigg, A., Cebon, J., Davis, I., Zalcberg, J., Ng, S., Appia, F., Green, M. (2003). A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours. Annals of Oncology, 14(5), 788-794. [More Information]
  • Gunawardana, D., Basser, R., Davis, I., Cebon, J., Mitchell, P., Underhill, C., Kilpatrick, T., Reardon, K., Green, M., Bardy, P., et al (2003). A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clinical Cancer Research, 9(6), 2056-2065. [More Information]
  • Jefford, M., Schnurr, M., Toy, T., Masterman, K., Shin, A., Beecroft, T., Tai, T., Shortman, K., Shackleton, M., Davis, I., et al (2003). Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood, 102(5), 1753-1763. [More Information]
  • Cebon, J., Jäger, E., Shackleton, M., Gibbs, P., Davis, I., Hopkins, W., Gibbs, S., Chen, Q., Karbach, J., Jackson, H., et al (2003). Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immunity, 3, 1-18. [More Information]

To update your profile click here. For support on your academic profile contact .